Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Metsera Inc (MTSR)

Metsera Inc (MTSR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,586,644
  • Shares Outstanding, K 105,293
  • Annual Sales, $ 0 K
  • Annual Income, $ -209,130 K
  • EBIT $ -179 M
  • EBITDA $ -179 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 16.69

Options Overview Details

View History
  • Implied Volatility 57.07% ( +6.35%)
  • Historical Volatility 85.82%
  • IV Percentile 29%
  • IV Rank 27.85%
  • IV High 163.24% on 09/19/25
  • IV Low 16.10% on 09/30/25
  • Put/Call Vol Ratio 2.22
  • Today's Volume 5,020
  • Volume Avg (30-Day) 5,120
  • Put/Call OI Ratio 1.97
  • Today's Open Interest 71,791
  • Open Int (30-Day) 31,189

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.56
  • Number of Estimates 1
  • High Estimate -0.56
  • Low Estimate -0.56
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.83 +60.47%
on 10/28/25
83.86 -0.81%
on 11/07/25
+30.28 (+57.24%)
since 10/07/25
3-Month
28.91 +187.77%
on 08/08/25
83.86 -0.81%
on 11/07/25
+52.29 (+169.28%)
since 08/07/25

Most Recent Stories

More News
Metsera Issues Statement in Response to Litigation Ruling

NEW YORK , Nov. 5, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to a ruling in the litigation filed against the...

MTSR : 83.18 (+2.00%)
Wall Street gains ground amid steady flow of earnings reports, upbeat economic updates

Stocks gained ground on Wall Street following several upbeat economic updates and a steady flow of quarterly reports from U.S. companies

GOOGL : 278.83 (-2.08%)
AVGO : 349.43 (-1.73%)
EXPE : 258.25 (+17.55%)
AXON : 602.51 (+2.62%)
IFF : 62.00 (-1.35%)
$IUXX : 25,059.81 (-0.28%)
PFE : 24.43 (-1.69%)
MSFT : 496.82 (-0.06%)
TSLA : 429.52 (-3.68%)
QCOM : 170.89 (-1.33%)
AMD : 233.53 (-1.75%)
$DOWI : 46,987.10 (+0.16%)
Halper Sadeh LLC Encourages TGNA, MTSR, CYBR Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  

TGNA : 19.95 (+0.55%)
MTSR : 83.18 (+2.00%)
CYBR : 503.87 (+0.29%)
$HAREHOLDER ALERT: The M&A Class Action Firm Encourages $hareholders to Act Before the Vote- CYBR, TGNA, MTSR, and GES

NEW YORK , Nov. 4, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for...

TGNA : 19.95 (+0.55%)
MTSR : 83.18 (+2.00%)
GES : 16.96 (+0.06%)
CYBR : 503.87 (+0.29%)
How major US stock indexes fared Tuesday, 11/4/2025

Stocks fell on Wall Street, pulled down by losses in the same big tech companies that have been the main drivers of the market’s rally so far this year

NVDA : 188.25 (+0.09%)
MTSR : 83.18 (+2.00%)
PLTR : 177.93 (+1.65%)
Losses for Big Tech pull Wall Street lower

Stocks fell on Wall Street, pulled down by losses in the same big tech companies that have been the main drivers of the market's rally so far this year

KMB : 103.85 (+3.06%)
NVDA : 188.25 (+0.09%)
MTSR : 83.18 (+2.00%)
$SPX : 6,728.80 (+0.13%)
EXPE : 258.25 (+17.55%)
$IUXX : 25,059.81 (-0.28%)
PFE : 24.43 (-1.69%)
MCD : 299.66 (+0.42%)
MSFT : 496.82 (-0.06%)
IREN : 62.38 (-6.84%)
YUM : 149.12 (+1.02%)
TSLA : 429.52 (-3.68%)
Novo Nordisk hikes Metsera bid to up to $10B in competition with rival Pfizer

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera

MTSR : 83.18 (+2.00%)
$SPX : 6,728.80 (+0.13%)
$DOWI : 46,987.10 (+0.16%)
$IUXX : 25,059.81 (-0.28%)
PFE : 24.43 (-1.69%)
Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal "Superior"

Novo Nordisk Amended Proposal Values Metsera at up to $ 86.20 per Share, a Total of Approximately $ 10.0 Billion

MTSR : 83.18 (+2.00%)
Metsera Issues Statement in Response to Litigation

NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by Pfizer:...

MTSR : 83.18 (+2.00%)
Pfizer sues to stop rival bid for drugmaker Metsera by Denmark's Novo Nordisk

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera

MTSR : 83.18 (+2.00%)
$SPX : 6,728.80 (+0.13%)
$DOWI : 46,987.10 (+0.16%)
$IUXX : 25,059.81 (-0.28%)
PFE : 24.43 (-1.69%)

Business Summary

Metsera Inc. is a clinical-stage biotechnology company developing next-generation injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight and related conditions. Metsera Inc. is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 91.02
2nd Resistance Point 86.90
1st Resistance Point 84.23
Last Price 83.18
1st Support Level 77.44
2nd Support Level 73.32
3rd Support Level 70.65

See More

52-Week High 83.86
Last Price 83.18
Fibonacci 61.8% 56.52
Fibonacci 50% 48.08
Fibonacci 38.2% 39.64
52-Week Low 12.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar